BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis - review
The vaccine Bacillus of Calmette Guérin (BCG) was originally developed in France as an oral vaccine against tuberculosis. The oral use of this vaccine was replaced by the parenteral route in almost all countries after the Lubeck disaster. In contrast, Brazil retained the oral delivery of the vaccine...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Fundação Oswaldo Cruz (FIOCRUZ)
2005-08-01
|
| Series: | Memorias do Instituto Oswaldo Cruz |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762005000500002 |
| _version_ | 1797715723456348160 |
|---|---|
| author | Thereza Christina Benévolo-de-Andrade Renata Monteiro-Maia Catherine Cosgrove Luiz Roberto R Castello-Branco |
| author_facet | Thereza Christina Benévolo-de-Andrade Renata Monteiro-Maia Catherine Cosgrove Luiz Roberto R Castello-Branco |
| author_sort | Thereza Christina Benévolo-de-Andrade |
| collection | DOAJ |
| description | The vaccine Bacillus of Calmette Guérin (BCG) was originally developed in France as an oral vaccine against tuberculosis. The oral use of this vaccine was replaced by the parenteral route in almost all countries after the Lubeck disaster. In contrast, Brazil retained the oral delivery of the vaccine until the mid-seventies when it was replaced by the intradermal route. This change in route of delivery was mainly secondary to pressure by medical practitioners based on the poor responses of oral immunized subjects to purified protein derivative (PPD) skin tests. Even after the change of route of delivery, Ataulpho de Paiva Foundation continued making the oral vaccine. Currently, BCG Moreau has been described as one of the most immunogenic and with fewer side effects than other BCGs. The genomics, proteomics and vaccine trials for oral BCG Moreau Rio de Janeiro are currently under investigation. In this review, we intend to describe the history of BCG Moreau Rio de Janeiro in Brazil. |
| first_indexed | 2024-03-12T08:10:54Z |
| format | Article |
| id | doaj.art-909e7e82e8b1458c8f1fe2742d1e98af |
| institution | Directory Open Access Journal |
| issn | 0074-0276 1678-8060 |
| language | English |
| last_indexed | 2024-03-12T08:10:54Z |
| publishDate | 2005-08-01 |
| publisher | Fundação Oswaldo Cruz (FIOCRUZ) |
| record_format | Article |
| series | Memorias do Instituto Oswaldo Cruz |
| spelling | doaj.art-909e7e82e8b1458c8f1fe2742d1e98af2023-09-02T19:07:07ZengFundação Oswaldo Cruz (FIOCRUZ)Memorias do Instituto Oswaldo Cruz0074-02761678-80602005-08-01100545946510.1590/S0074-02762005000500002BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis - reviewThereza Christina Benévolo-de-AndradeRenata Monteiro-MaiaCatherine CosgroveLuiz Roberto R Castello-BrancoThe vaccine Bacillus of Calmette Guérin (BCG) was originally developed in France as an oral vaccine against tuberculosis. The oral use of this vaccine was replaced by the parenteral route in almost all countries after the Lubeck disaster. In contrast, Brazil retained the oral delivery of the vaccine until the mid-seventies when it was replaced by the intradermal route. This change in route of delivery was mainly secondary to pressure by medical practitioners based on the poor responses of oral immunized subjects to purified protein derivative (PPD) skin tests. Even after the change of route of delivery, Ataulpho de Paiva Foundation continued making the oral vaccine. Currently, BCG Moreau has been described as one of the most immunogenic and with fewer side effects than other BCGs. The genomics, proteomics and vaccine trials for oral BCG Moreau Rio de Janeiro are currently under investigation. In this review, we intend to describe the history of BCG Moreau Rio de Janeiro in Brazil.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762005000500002BCG Moreau Rio de Janeirooral vaccinereview |
| spellingShingle | Thereza Christina Benévolo-de-Andrade Renata Monteiro-Maia Catherine Cosgrove Luiz Roberto R Castello-Branco BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis - review Memorias do Instituto Oswaldo Cruz BCG Moreau Rio de Janeiro oral vaccine review |
| title | BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis - review |
| title_full | BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis - review |
| title_fullStr | BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis - review |
| title_full_unstemmed | BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis - review |
| title_short | BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis - review |
| title_sort | bcg moreau rio de janeiro an oral vaccine against tuberculosis review |
| topic | BCG Moreau Rio de Janeiro oral vaccine review |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762005000500002 |
| work_keys_str_mv | AT therezachristinabenevolodeandrade bcgmoreauriodejaneiroanoralvaccineagainsttuberculosisreview AT renatamonteiromaia bcgmoreauriodejaneiroanoralvaccineagainsttuberculosisreview AT catherinecosgrove bcgmoreauriodejaneiroanoralvaccineagainsttuberculosisreview AT luizrobertorcastellobranco bcgmoreauriodejaneiroanoralvaccineagainsttuberculosisreview |